A novel indication of thioredoxin-interacting protein as a tumor suppressor gene in malignant glioma

Zhang,Pengxing; Gao,Jinxi; Wang,Xin; Wen,Weihong; Yang,Hongwei; Tian,Yongji; Liu,Nan; Wang,Zhen; Liu,Hui; Zhang,Yongsheng; Tu,Yanyang

doi:10.3892/ol.2017.6397

A novel indication of thioredoxin-interacting protein as a tumor suppressor gene in malignant glioma

Authors:
- Pengxing Zhang
- Jinxi Gao
- Xin Wang
- Weihong Wen
- Hongwei Yang
- Yongji Tian
- Nan Liu
- Zhen Wang
- Hui Liu
- Yongsheng Zhang
- Yanyang Tu
View Affiliations

Affiliations: Department of Experimental Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Department of Neurosurgery, Fuzhou General Hospital of The People's Liberation Army, Fuzhou, Fujian 350025, P.R. China, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA, Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: June 16, 2017 https://doi.org/10.3892/ol.2017.6397
Pages: 2053-2058
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant glioma, the most common form of primary brain tumor, is associated with substantial morbidity and mortality, owing to the lack of response shown by patients to conventional therapies. Additional therapeutic targets and effective treatment options for these patients are therefore required. In the present study, a possible association of thioredoxin-interacting protein (TXNIP) with malignant glioma was evaluated. Initially, semi-quantitative and quantitative analysis of the expression levels of TXNIP in clinical specimens of primary glioma was performed via immunohistochemistry (IHC) and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), respectively, and expression levels were further correlated to the overall survival time of the patients. The proliferative, migratory and invasive properties of the glioblastoma U251 cell line, engineered to downregulate TXNIP by lentiviral transfection of a specific short hairpin RNA, were evaluated by means of in vitro assays. Consequently, IHC and RT‑qPCR analysis revealed a negative association between the expression level of TXNIP and the histopathological grade of the tumor. Higher TXNIP expression level was associated with extended patient survival time. In vitro analysis revealed increased growth, migration and invasion in U251 cells with downregulated TXNIP expression compared with their non‑transfected counterparts. These findings strongly indicate that TXNIP functions as a tumor suppressor in malignant glioma cells and underscore its potential as a novel therapeutic target and prognostic indicator of the condition.

View Figures

View References

1	Chang L, Su J, Jia XZ and Ren H: Treating malignant glioma in Chinese patients: Update on temozolomide. Onco Targets Ther. 7:235–244. 2014.PubMed/NCBI
2	Davis FG and McCarthy BJ: Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther. 1:395–401. 2001. View Article : Google Scholar : PubMed/NCBI
3	Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, Bao Z, Wang Y, Qiu X and Jiang T: Management and survival rates in patients with glioma in China (2004–2010): A retrospective study from a single-institution. J Neurooncol. 113:259–266. 2013. View Article : Google Scholar : PubMed/NCBI
4	Chen C, Xu T, Lu Y, Chen J and Wu S: The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol. 20:223–230. 2013. View Article : Google Scholar : PubMed/NCBI
5	Chen KS and DeLuca HF: Isolation and characterization of a novel cDNA from HL-60 cells treated with 1, 25-dihydroxyvitamin D-3. Biochim Biophys Acta. 1219:26–32. 1994. View Article : Google Scholar : PubMed/NCBI
6	Kim SY, Suh HW, Chung JW, Yoon SR and Choi I: Diverse functions of VDUP1 in cell proliferation, differentiation, and diseases. Cell Mol Immunol. 4:345–351. 2007.PubMed/NCBI
7	Patwari P, Chutkow WA, Cummings K, Verstraeten VL, Lammerding J, Schreiter ER and Lee RT: Thioredoxin-inde-pendent regulation of metabolism by the alpha-arrestin proteins. J Biol Chem. 284:24996–25003. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zhou J, Yu Q and Chng WJ: Txnip (vdup-1, tbp-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int J Biochem Cell Biol. 43:1668–1673. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zhou JB and Chng WJ: Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer. Mitochondrion. 13:163–169. 2013. View Article : Google Scholar : PubMed/NCBI
10	Yoshihara E, Masaki S, Matsuo Y, Chen Z, Tian H and Yodoi J: Thioredoxin/Txnip: Redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol. 4:5142014. View Article : Google Scholar : PubMed/NCBI
11	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q and Chng WJ: The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 118:2830–2839. 2011. View Article : Google Scholar : PubMed/NCBI
14	Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA and Richon VM: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci. 99:pp. 11700–11705. 2002; View Article : Google Scholar : PubMed/NCBI
15	Yamaguchi F, Takata M, Kamitori K, Nonaka M, Dong Y, Sui L and Tokuda M: Rare sugar d-allose induces specific up-regulation of txnip and subsequent G1 cell cycle arrest in hepatocellular carcinoma cells by stabilization of p27kip1. Int J Oncol. 32:377–385. 2008.PubMed/NCBI
16	Song H, Cho D, Jeon JH, Han SH, Hur DY, Kim YS and Choi I: Vitamin d (3) up-regulating protein 1 (vdup1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species. Immunol Lett. 86:235–247. 2003. View Article : Google Scholar : PubMed/NCBI
17	Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, Li W, Hu B, Cheng SY and Li M: Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res. 73:990–999. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zhang P, Pang X and Tu Y: Thioredoxin-interacting protein as a common regulation target for multiple drugs in clinical therapy/application. Cancer Transl Med. 1:26–30. 2015. View Article : Google Scholar
19	Han SH, Jeon JH, Ju HR, Jung U, Kim KY, Yoo HS, Lee YH, Song KS, Hwang HM, Na YS, et al: VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene. 22:4035–4046. 2003. View Article : Google Scholar : PubMed/NCBI
20	Le Jan S, Le Meur N, Cazes A, Philippe J, Le Cunff M, Léger J, Corvol P and Germain S: Characterization of the expression of the hypoxia-induced genes neuritin, txnip and IGFBP3 in cancer. FEBS Lett. 580:3395–3400. 2006. View Article : Google Scholar : PubMed/NCBI
21	Lee KN, Kang HS, Jeon JH, Kim EM, Yoon SR, Song H, Lyu CY, Piao ZH, Kim SU, Han YH, et al: Vdup1 is required for the development of natural killer cells. Immunity. 22:195–208. 2005. View Article : Google Scholar : PubMed/NCBI
22	Erkeland SJ, Palande KK, Valkhof M, Gits J, Danen-van Oorschot A and Touw IP: The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients. Leuk Res. 33:1367–1371. 2009. View Article : Google Scholar : PubMed/NCBI
23	Dutta KK, Nishinaka Y, Masutani H, Akatsuka S, Aung TT, Shirase T, Lee WH, Yamada Y, Hiai H, Yodoi J and Toyokuni S: Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Lab Invest. 85:798–807. 2005. View Article : Google Scholar : PubMed/NCBI
24	Ahsan MK, Masutani H, Yamaguchi Y, Kim YC, Nosaka K, Matsuoka M, Nishinaka Y, Maeda M and Yodoi J: Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. Oncogene. 25:2181–2191. 2006. View Article : Google Scholar : PubMed/NCBI
25	Cheng YD, Geng H, Cheng SH, Liang P, Bai Y, Li J, Srivastava G, Ng MH, Fukagawa T, Wu X, et al: The KRAB Zinc finger protein ZNF382 is a general, proapoptotic tumor suppressor repressing multiple oncogenes and frequently silenced in multiple carcinomas. Cancer Res. 70:6516–6526. 2010. View Article : Google Scholar : PubMed/NCBI
26	Cheng YD, Liang P, Geng H, Wang Z, Li L, Cheng SH, Ying J, Su X, Ng KM, Ng MH, et al: A novel 19q13 nucleolar zinc finger protein suppresses tumor cell growth through inhibiting ribosome biogenesis and inducing apoptosis but is frequently silenced in multiple carcinomas. Mol Cancer Res. 10:925–936. 2012. View Article : Google Scholar : PubMed/NCBI
27	Wang S, Cheng Y, Du W, Lu L, Zhou L, Wang H, Kang W, Li X, Tao Q, Sung J and Yu J: Zinc-finger protein 545 is a novel tumour suppressor that acts by inhibiting ribosomal RNA transcription in gastric cancer. Gut. 62:833–841. 2013. View Article : Google Scholar : PubMed/NCBI
28	Kato T, Shimono Y, Hasegawa M, Jijiwa M, Enomoto A, Asai N, Murakumo Y and Takahashi M: Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress. Cancer Res. 69:3597–3604. 2009. View Article : Google Scholar : PubMed/NCBI
29	Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 102:pp. 673–678. 2005; View Article : Google Scholar : PubMed/NCBI
30	Yan GR, Xu SH, Tan ZL, Liu L and He QY: Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics. Proteomics. 11:912–920. 2011. View Article : Google Scholar : PubMed/NCBI